Evidera operates as a wholly owned subsidiary of Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO). Evidera was created in 2013 as an independent company under the ownership of Symphony Technology Group (STG) following the acquisition of long-standing health economics, outcomes research, market access, epidemiology and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group and Archimedes.
Since it was formed, Evidera has worked with all of the top 20 biopharma companies, and is a preferred provider for most of the top 50. Evidera scientists and consultants publish more than 150 peer-reviewed articles per year and have more than 1,100 studies in progress across all major therapeutic areas.
Evidera’s 300 researchers and consultants have expertise working in all developed and many developing countries.
The global biosimulation market is forecasted to reach a figure of about US$ 1,750 Mn in 2022 and is poised to exhibit a robust CAGR in the period of assessment. Posted via Industry Today. Follow us on Twitter @IndustryToday